Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders

Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results

Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET

Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital

Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

Vaxart to Host Upcoming Conference Calls

Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026